A B S T R A C T Exposure of human blood polymorphonuclear leukocytes (PMN) to purified active plasma kallikrein resulted in PMN aggregation when kallikrein was present at concentrations ranging from 0.4 to 0.6 U/ml (0.18-0.27 MM). Kallikrein-induced PMN aggregation was not mediated through C5-derived peptides, because identical responses were observed whether or not kallikrein had been preincubated with an antibody to C5. Moreover, kallikrein was specific for aggregating PMN, because no aggregation was observed with Factor XII active fragments (23 nM), Factor XIa (0.6 U/ml or 15 nM), thrombin (1.6 MM), plasmin (2 AM), porcine pancreatic elastase (2 ,M), bovine pancreatic chymotrypsin (2 ,uM), or bradykinin (1 MM). Bovine pancreatic trypsin (2 MAM) aggregated PMN, but to a lesser extent than kallikrein (0.18 MM). Kal- 
INTRODUCTION
During the contact activation of blood coagulation, fibrinolysis, and kinin generation, human plasma prekallikrein undergoes a limited proteolytic cleavage, resulting in the formation of plasma kallikrein, a serine protease (1) . Once formed, plasma kallikrein activates Factor XII to Factor XIIa, plasminogen to plasmin, and liberates bradykinin from high molecular weight kininogen (1) . In addition, partially purified human plasma kallikrein preparations have been reported to enhance blood polymorphonuclear leukocyte (PMN)' chemotaxis (2) and aerobic glucose metabolism (3) . However, these conclusions were recently challenged by the observation that purified rabbit kallikrein was not directly chemotactic for rabbit PMN (4) . In this latter report, kallikrein-associated chemotactic activity was observed only after rabbit plasma kallikrein had been incubated with rabbit C5, thereby generating a C5a-like peptide (4) .
In this communication, we describe the effect of highly purified human plasma kallikrein on human PMN, using cell aggregation and oxygen consumption as criteria for neutrophil activation.
METHODS
Materials. Prekallikrein, Factor XII fragments, and Factor XIa were purified to homogeneity as described elsewhere (5-7). Prekallikrein was activated to kallikrein using Factor XII fragments (5) , which were not removed after activation. Thus kallikrein ( and antiserum to human C5 (Atlantic Antibodies, Scarborough, ME) were purchased from the designated supplier. All other reagents used were reagent grade. Normal human serum was activated with zymosan as described (9) . PMN isolation. PMN in >98% purity with <1 platelet/ 1,000 cells were isolated from ADP-treated heparinized venous blood by dextran sedimentation and Ficoll-Hypaque gradient centrifugation (10) . The cells were washed four times. For cell aggregation, purified PMN were suspended in phosphate-buffered saline, pH 7.4, containing 5 mM glucose (10) . For oxygen uptake determination, purified PMN were suspended in Krebs-Ringer phosphate, pH 7.4. PAIN aggregation. Aggregometry was performed as a modification (10) of the method described by Craddock et al. (11) in a standard platelet aggregometer (Payton Associates, Inc., model 300B) (10) . To a silicone-coated euvette containing a Teflon stir bar revolving at 900 rpm, 0.45 ml of a suspension containing 1.5 X 107 PMN/ml was added, along with the addition of Ca2" (1.5 mM) and Mg2" (1.5 mM). After a 2-min delay to allow warming of the cells to 37°C, 50 pl of the aggregant was added, and the resulting changes in light transmission were recorded at AT. To provide the necessary amplification for a well defined aggregation wave, the aggregometer-recorder system was calibrated with a suspension containing 0.5-0.75 X 107 PMN/ml.
Oxygen consumption. Oxygen consumption was measured by the use of an oxygen electrode (model 53, Yellow Springs Instrument Co., Yellow Springs, OH). A suspension of 107 PMN in 2.9 ml of Krebs-Ringer-phosphate solution was placed in the reaction vessel. After 5-min incubation at 37°C in the presence of NaN3 (1 mM), 0.1 ml of the stimulant solution was added. Oxygen consumption was recorded for 10 min.
Statistical method. Results were expressed as mean±1 SD. The significance of differences between means was assessed by unpaired Student's t tests.
RESULTS
Purified human plasma kallikrein (final concentration 0.4-0.6 U/ml or 0.18-0.27 ,M1) aggregated blood PMN provided Ca2" (1.5 mM) and Mg2" (1.5 mM) were present during the reaction (Fig. IA) . Kallikrein-induced PMN aggregation was confirmed by phase microscopy. In contrast, no aggregation was observed when PMN were incubated with prekallikrein (0.6 U/ml or 0.27 AM), or with kallikrein (0.6 U/ml or 0.27 AM) that had been previously inactivated by SBTI or DFP (Fig. 1A,  d) . Similarly, Factor XII active fragments (0.023 MM), Factor XIa (0.6 U/ml or 0.015 MM), thrombin (1.6 ,M), plasmin (2 ,uM), and bradykinin (1 MM) failed to aggregate PMN (Fig. 1A, d) . Additional experiments revealed that porcine pancreatic elastase (2 ,M) or bovine pancreatic chymotrypsin (2 MAM) did not aggregate PMN (Fig. 1B, b ), but that aggregation was observed when PMN were exposed to bovine pancreatic trypsin (2 MM) (Fig. 1B, a) . This response was absent when PMN were exposed to trypsin that had been previously inactivated by SBTI (Fig. IB, b) .
Quantitation of PMN aggregation indicated that significant responses were observed with kallikrein concentrations ranging from 0.4 to 0.6 U/ml or 0.18 to 0.27 uM (Table I) (Fig. 1B, a) was smaller than the response observed with 0.025 MM FMLP (Fig. lB, c) .
To exclude the possibility of the participation of C5-derived peptides in kallikrein-induced PMN aggregation, kallikrein was preincubated with an antiserum to C5. This treatment abrogated PMN aggregation by a 1:10 dilution of zymosan-activated (32 mg/ml) human serum (not shown). Identical aggregation responses to kallikrein (0.5 U/ml or 0.23 MM) were observed, whether or not the enzyme had been exposed to the antiserum to C5 (37.3±2.4 vs. 41.3±3.2, P > 0.1) ( Table I) .
For assessment of whether the interaction between kallikrein and PMN was associated with an increase in PMN oxidative metabolism, PMN were exposed to various concentrations of kallikrein and the oxygen consumption was determined. A 4.4-5.8-fold increase in oxygen consumption was observed when PMN were incubated with kallikrein concentrations ranging from 0.4 to 0.6 U/ml or 0.18 to 0.27 MM (Table II) . For comparison, PMN exposed to 0.2 MAM FMLP increased their oxygen consumption by 6.2 times (Table II) . DISCUSSION The results presented in this report support the conclusion that highly purified human plasma kallikrein is a specific and potent aggregant agent for human blood PMN, as well as increases their oxidative metabolism. (Fig. 1A, d ). Only trypsin was found to aggregate PMN, but less efficiently than did kallikrein (Fig. 1B, Table I ).
Active kallikrein was required for PMN aggregation because prekallikrein, or kallikrein that had been inactivated by DFP or SBTI, failed to induce any response (Fig. IA, d) . Similarly, trypsin that had been inactivated by SBTI did not aggregate the cells (Fig.  1B, b) . The need for an active enzyme species for PMN aggregation strongly suggested that PMN were activated as a result of a proteolytic cleavage. Kallikrein as well as trypsin liberate bradykinin from high molecular weight kininogen (1). However, bradykinin was not responsible for PMN aggregation because this hypothesis was directly tested (Fig. IA, d ). C5-derived peptides aggregate human PMN (11) . In addition, rabbit kallikrein has been shown to cleave rabbit C5, thereby liberating chemotactic peptides (4). Thus, experiments were designed to determine if our kallikrein preparation contained C5-derived peptides, or if a significant amount of C5 was present on the surface of purified human PMN. The kallikrein preparation did not contain C5-derived peptides because no differences in PMN aggregation were observed, whether or not kallikrein had been preincubated with an antiserum to C5 (Table I) . Moreover, it is unlikely that human PMN had significant surface-associated C5 because plasmin, which liberates chemotactic peptides from C5 (l13), failed to aggregate the cells (Fig. 1A,  d) . Therefore, plasma kallikrein appears to be a direct aggregant agent for human PMN. Moreover, because similar responses are observed with optimal doses of FMLP (10) or with kallikrein concentration that may be generated in vivo (14) , kallikrein is a potent aggregant agent for PMN.
The interaction between plasma kallikrein and PMN was associated with stimulation of the respiratory Plasma Kallikrein Aggregates Blood Neutrophils 1201 burst, as indicated by an increased oxygen uptake observed when the cells were exposed to the enzyme (Table II) . A parallel observation was made by others (3) , who showed that partially purified kallikrein increased both PMN aerobic glycolysis rate and hexose monophosphate shunt activity (3) .
In experimental animals, activation of Factor XII, and thus plasma kallikrein generation, results in the development of acute leukostasis, mainly in the gallbladder wall and the pulmonary blood vessels (15) . In man, neutropenia is often observed with diseases such as gram-negative septicemia or typhoid fever (16) , which are known to be associated with prekallikrein activation (14) . Kallikrein-induced PMN aggregation may be an important factor for the occurrence of neutropenia and leukostasis in conditions associated with activation of the contact phase system.
